Weed Week: US looks to decriminalise cannabis and Victoria Greens say legal weed could mean $1.21bn in revenue
Health & Biotech
Health & Biotech
Link copied to
Big news out of the US last week, with President Joe Biden announcing plans to pardon all federal offenses of cannabis possession in the USA – highlighting the first significant step towards decriminalisation.
The announcement also marks initial steps towards the potential shift to reclassify cannabis on a federal level, with President Biden encouraging governors to advance steps to pardon possession charges at a state level and will task the Department of Health and Human Services and Attorney General Merrick Garland to expeditiously review how cannabis is scheduled under federal law.
For pot stocks with a lot of skin in the US game this could be a real boost for operations in North America.
Plus, word on the street is that any positive legislative change could provide the catalyst for major US institutions to increase exposure to the sector.
And on our side of the pond, the Victorian Greens have proposed for cannabis to be legalised for adults ahead of the State election in November.
The plan would see a 30% tax similar to alcohol, which could potentially add $1.21 billion in revenue over a decade.
BREAKING: Today the Victorian Greens will launch their plan to legalise and regulate cannabis in Victoria from 2024.
For decades our state has treated drug use as a criminal issue rather than a health one, putting drug users at great risk.
It’s high-time we changed that.
— Samantha Ratnam – Leader of the Victorian Greens (@SamanthaRatnam) October 9, 2022
A total of 16 companies were in the green, with 10 companies flat and 11 stocks in the red.
The company has secured Victorian Government licences to enable the operation of its newly commissioned Melbourne Distribution Centre (MDC).
The two licences permit the supply of Schedule 2 (all products), Schedule 3 (all products), Schedule 4 (all products) and Schedule 8 (cannabis, THC products) products to pharmacies from the MDC.
“The highly secure, state-of-the-art MDC facility can support a significant uplift in medicinal cannabis sales volume through our market leading CanView platform,” CEO Rodney Cocks said.
It also puts product closer to pharmacies and patients while underpinning business continuity contingency planning.”
IHL says it had a positive pre-Investigational New Drug Application (pre-IND) meeting with the US Food and Drug Administration (FDA) on its IHL-216A drug, which is a combination of CBD and isoflurane (ISO) that is being developed for treatment of traumatic brain injury and concussion (TBI).
“Feedback from the FDA in the pre-IND meeting indicated that the agency is highly interested in the development of IHL-216A for treatment of traumatic brain injury,” chief scientific officer Dr Mark Bleackley said.
“Their responses covered all aspects of the proposed development and engaged a range of disciplinary experts that provided useful insight on all aspects of our development plan.
“The FDA has provided essential advice on inhaled drug development that will guide the most efficient development of IHL-216A.”
LGP has partnered with German cannabis pioneer Cannamedical for the supply of bulk medicinal cannabis from Denmark to Germany, with a potential value of over $4.5 million (€3 million) over two years.
The agreement represents LGP’s fourth contract for the supply of medicinal cannabis into Germany and, together with Four20 Pharma, Illios Sante and Demecan, rounds out its wholesaling portfolio with the largest independent, own-brand medicinal cannabis distributor in Germany.
At Stockhead we tell it like it is. While Incannex Healthcare is a Stockhead advertiser, it did not sponsor this article.